Download the latest edition of HCP’s Serialization Playbook that will bring you up to date on DQSA/DSCSA, and what it means for your serialization efforts. Learn More »
The European vaccines market is predicted to witness significant growth in the next few years, due to increased investment in new vaccine development, utilization of novel technologies, and a promising late-stage pipeline.
According to new research by Frost & Sullivan, “Analysis of the European Vaccines Market, the European vaccines market is estimated to reach earned revenues of $12.05 billion in 2018 at a compound annual growth rate (CAGR) of 9.6% from 2011-2018.
"The future growth of the vaccine industry is likely to be propelled by the adult vaccines segment," said Frost & Sullivan senior research analyst Aiswariya Chidambaram. "The tremendous success rates of the recently launched influenza and HPV vaccines have attracted the attention of market participants toward the adult vaccines. The vast majority of the vaccines in pipeline are novel, innovative vaccines based on new antigens, targeting malaria, tuberculosis, dengue fever, allergies, and herpes.
The high unmet needs of diseases prevalent in the developing world present huge opportunities for market growth and are also attracting investment from governments to reduce healthcare costs and private investors for philanthropic and commercial reasons. Alongside technology innovation, this increased attention on vaccine R&D is “likely to revolutionize the vaccine industry from prophylactic to therapeutic vaccines,” the report said.
However there are still economic and regulatory challenges that face vaccine manufacturers on their quest to commercialization.
The Frost and Sullivan analysis also showed that anticipation of capacity demand is still a key challenge, especially during a pandemic. "Speculation of vaccine production capacity considering unanticipated needs such as pandemic outbreaks, epidemics, and bioterrorism is likely to have a huge impact on the growth and sustenance of vaccine manufacturers in Europe," added Chidambaram. "Vaccine manufacturers are under the compulsion to maintain excess reserve supply owing to the tender-based vaccine procurement, lest they miss out on huge business opportunities."
Whatever the known challenges vaccine development is set for rapid growth, spurred on by global unmet need and innovation in the field.
--Article contributed by Cold Chain IQ